

22nd Annual MEETING & EXPOSITION

September 17-20, 2025 • Toronto, Canada



Daily Program Schedule

Wednesday, September 17, 2025

06:00 - 18:30	REGISTRATION OPEN	Level 600 Prefunction
08:00 - 08:45	OPENING CEREMONY P D V	Hall FG
08:00 - 08:05	Welcome	
08:05 - 08:15	Pioneers in Myeloma	
08:15 - 08:45	President's Address	Philippe Moreau
08:45 - 09:30	KEYNOTE P D V	Hall FG
	<i>Co-chairs: Philippe Moreau and Keith Stewart</i>	
08:45 - 09:15	Tumor-reactive $\gamma\delta$ T cells Predict Responses to Antibody Drug Conjugates	Tak Mak
09:15 - 09:30	Q&A	
09:30 - 10:50	CORE SESSION 1: PRECURSOR DISEASE P D V	Hall FG
	<i>Chair: Vincent Rajkumar, Co-chair: Maria-Victoria Mateos</i>	
09:30 - 09:40	Genomic profiling	Mehmet Samur
09:40 - 09:50	Microenvironment	Madhav Dhodapkar
09:50 - 10:00	What else is important in the transition from Smoldering to MM?	Sigurdur Kristinsson
10:00 - 10:10	Clinical management of precursor conditions	Natalie Callander
10:10 - 10:25	Future Directions and Challenges	Sagar Lonial
10:25 - 10:50	Round Table discussion	Leif Bergsagel, Irene Ghobrial, Jesus San Miguel, Kwee Yong

11:00 - 11:50	ABSTRACT SESSION 1 P D	Room 701
	<i>Co-chairs: Rafat Abonour and Meral Beksac</i>	
11:00 - 11:10	OA-13: Post-Induction Outcomes and Updated Minimal Residual Disease Analysis from GMMG-HD10/DSMM-XX (MajesTEC-5): a Study of Teclistamab-Based Induction Regimens in Newly Diagnosed Multiple Myeloma (NDMM)	Marc Raab
11:10 - 11:20	OA-14: Cevostamab plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM): Phase I dose-expansion results from the CAMMA 1 study	Hira Mian
11:20 - 11:30	OA-07: Elranatamab in Combination With Daratumumab and Lenalidomide (EDR) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results from MagnetisMM-6 Part 1	Suzanne Trudel
11:30 - 11:40	OA-02: Sustained Remission After Limited-Duration of Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma	Meera Mohan
11:40 - 11:50	OA-35: TRIgnite- 1study, Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—dose escalation (DE) results.	Hang Quach
11:00 - 11:50	ABSTRACT SESSION 2 P D	Room 718
	<i>Co-chairs: Manoj Bhasin and Jill Corre</i>	
11:00 - 11:10	OA-29: In situ visualisation of BCMA bispecific antibody and the myeloma immune microenvironment	Jeremy Er
11:10 - 11:20	OA-31: A Comprehensive Map of Genomic Drivers of Resistance to Anti-BCMA Immunotherapies in Multiple Myeloma	Francesco Maura
11:20 - 11:30	OA-10: MZB1-Directed HLA-Dependent CAR T Cells for Targeting B-Cell Malignancies	Elena Maroto Martin
11:30 - 11:40	OA-15: S100A8/A9 Promotes T Cell Exhaustion and Impairs Response to Bispecific Therapy in Multiple Myeloma	Oliver Van Oekelen
11:40 - 11:50	OA-11: Baseline and Longitudinal Immune and Inflammatory Correlates of Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma	Tarek Mouhieddine
12:00 - 16:30	EXHIBITION OPEN	Hall E
12:00 - 13:00	LUNCH AND POSTER SESSIONS P	Hall E
12:00 - 12:50	POSTER DISCUSSION P L	714A
	<i>Co-chairs: Hartmut Goldschmidt and Simon Harrison</i>	
12:00 - 12:02	Introduction	
12:02 - 12:08	PA-324: AKR1B1/NAT10 mediate IL4I1 ac4C modification to regulate tryptophan metabolism and promote multiple myeloma proliferation	Rongfang Wei

12:08 - 12:14	PA-039: Differential impact of BCMA (TNFRSF17) extracellular domain mutations on in vitro potency of elranatamab versus teclistamab	Maria Josic
12:14 - 12:20	PA-094: Early Mortality Associated with Real-World Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma	Carlyn Rose Tan
12:20 - 12:26	PA-307: Iberdomide (IBER) treatment (Tx) enhances manufactured chimeric antigen receptor (CAR) T cell expansion and functionality and is immunostimulatory in patients post-CAR T cell therapy	Michael Amatangelo
12:26 - 12:32	PA-374: MGUS Prevalence from a Large-Scale Community Study from Rural India (IMAGE-002B Study)	Uday Yanamandra
12:32 - 12:38	PA-255: Multi-hit Cytogenetics Risk Events Associated with IFN-I Suppression across TME of NDMM Patients and Poor Outcomes	William Pilcher
12:38 - 12:44	PA-180: Revealing Clonal Evolution and Assessing Immune Reconstitution in Multiple Myeloma Using Next-Generation Sequencing-Based Minimal Residual Disease (NGS-MRD) Analysis	Yuntong Liu
12:44 - 12:50	PA-529: Risk of infections after bispecific antibodies targeting anti-B-cell maturation antigen (BCMA) in multiple myeloma-intravenous immunoglobulin (IVIg) significantly lowers the risk of infection	Amandeep Godara
<hr/>		
12:00 - 12:50	MEET THE EXPERTS P L	
Room 714B	MRD in clinical practice	Ben Derman and Noemi Puig
Room 716A	MGRS - diagnosis and management	Ramon Garcia Sanz and Victor Jimenez Zepeda
Room 716B	Amyloidosis	Angela Dispenzieri and Efsthios Kastritis
<hr/>		
13:00 - 14:30	INDUSTRY SYMPOSIUM SUPPORTED BY BRISTOL MYERS SQUIBB P D V <i>Innovative Approaches for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma</i> <i>Chair: Luciano Costa</i>	Hall FG
13:00 - 13:10	Welcome and Introduction <i>Optimizing CAR T Outcomes and Exploring Next-Generation Advances</i>	
13:10 - 13:25	Improving patient care: lessons from real-world evidence	Krina Patel
13:25 - 13:40	Addressing unmet needs in RRMM: new therapies in development	Rahul Banerjee
13:40 - 13:50	Q&A and roundtable discussion <i>Overcoming challenges of T-cell exhaustion with novel protein degraders</i>	
13:50 - 14:05	Can novel protein degraders mitigate T-cell exhaustion in MM? Learnings from preclinical studies	Karthik Ramasamy
14:05 - 14:20	Exploring clinical approaches	Joshua Richter
14:20 - 14:30	Q&A and roundtable discussion	
14:30	Closing Remarks	Luciano Costa

14:30 - 15:50	CORE SESSION 2: RISK ADAPTED MANAGEMENT P D V	Hall FG
	<i>Chair: Thierry Facon, Co-chair: Francesca Gay</i>	
14:30 - 14:40	Risk assessment of newly diagnosed MM: genetic and biological risk factors	Faith Davies
14:40 - 14:50	Age or fitness - who should get a transplant?	Aurore Perrot
14:50 - 15:00	Optimal treatment for high risk mm	Martin Kaiser
15:00 - 15:10	Frailty adapted therapy in NDMM	Ashley Rosko
15:10 - 15:25	Future Directions and Challenges	Sonja Zweegman
15:25 - 15:50	Round Table discussion	Gordon Cook, Arleigh McCurdy, Hira Mian
16:00 - 16:30	NETWORKING BREAK	Hall E
16:30 - 17:20	ABSTRACT SESSION 3 P D	Room 701
	<i>Co-chairs: Andrzej Jakubowiak and Robert Orlowski</i>	
16:30 - 16:40	OA-17: MRI Response According to MY-RADS Correlates with MRD Negativity After Induction in Newly Diagnosed Multiple Myeloma: Results from the GMMG-HD7 Trial	Marina Hajiyianni
16:40 - 16:50	OA-18: The value of progression-free survival (PFS) from the perspectives of patients with multiple myeloma (MM) and treating physicians: quantitative research findings from eight countries	Aaron Rosenberg
16:50 - 17:00	OA-19: Prospective evaluation of response assessment in newly-diagnosed multiple myeloma with combined use of 18F-FDG-PET/CT, whole-body diffusion-weighted MRI and MRD by next-generation sequencing	Marco Talarico
17:00 - 17:10	OA-21: Dynamic Frailty Analysis of Transplant-Ineligible (TIE) Patients with NDMM in the Phase 3 MAIA and CEPHEUS Trials of Daratumumab (Dara) + Lenalidomide-Dexamethasone (Rd) and Bortezomib-Rd (VRd)	Hira Mian
17:10 - 17:20	OA-20: Temporal Trends in Infectious Risk Among Multiple Myeloma Patients Treated with Daratumumab: A Meta-Analysis	Alissa Visram
16:30 - 17:20	ABSTRACT SESSION 4 P D	Room 718
	<i>Co-chairs: Diana Cirstea and Francesco Maura</i>	
16:30 - 16:40	OA-27: Composition and functional state of T and NK cells in extramedullary myeloma tumor microenvironment	Anjana Anilkumar Sithara
16:40 - 16:50	OA-49: Insights from Cytogenetic Subgroup Analyses in the GMMG-CONCEPT trial with Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma	Lisa Leypoldt
16:50 - 17:00	OA-28: Midnolin downregulation promotes myelomagenesis via impacting ubiquitination independent pathway of protein degradation	Anna Besschetnova

17:00 - 17:10	OA-72: Deciphering Myeloid Cell Dynamics within the Osteolytic Lesion Tumor Microenvironment to Overcome Immunosuppression in Multiple Myeloma	Joshua Rivera
17:10 - 17:20	OA-73: Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myeloma	Denis Ohlstrom
17:30 - 18:20	IMWG-IMS CONSENSUS WORKSHOP SUMMARIES P D V <i>Co-chairs: Vincent Rajkumar and Joan Blade</i>	Hall FG
17:30 - 17:50	Updated IMWG/IMS Uniform Response Criteria	Shaji Kumar
17:50 - 18:05	Q&A	
18:05 - 18:20	IMS Educational Initiatives	Noopur Raje
18:30 - 20:00	TRAINEE FORUM AND NETWORKING RECEPTION P	Room 501

Thursday, September 18, 2025

06:00 - 18:00	REGISTRATION OPEN	Level 600 Prefunction
07:00 - 08:00	LMIC BREAKFAST: MANAGING MYELOMA WITH LIMITED RESOURCES - CHALLENGES AND OPPORTUNITIES P <i>Panelists: Jelena Bila, Lindokuhle Goqwana, Angelo Maiolino, Uday Yanamandra</i>	Soco Ballroom A, Delta Hotel
08:00 - 09:00	INDUSTRY SYMPOSIUM SUPPORTED BY GSK P D V <i>Chair: Joseph Mikhael</i>	Hall FG
08:00 - 08:10	What more can we do: The first relapse treatment landscape	Paul Richardson
08:10 - 08:25	The road ahead: Driving outcomes in RRMM	Peter Voorhees
08:25 - 08:35	Leaving no patient behind: Patient preferences at relapse	Martine Elias and Lisa Leypoldt
08:35 - 08:45	Optimizing patient outcomes: Balancing efficacy and safety	Joseph Mikhael
08:45 - 09:00	Discussion/Audience Q&A	
09:00 - 10:20	CORE SESSION 3: IMMUNOTHERAPY P D V <i>Chair: Nikhil Munshi, Co-chair: Kenneth Anderson</i>	Hall FG
09:00 - 09:10	Role of target/tumor as mechanism of resistance to CAR T-cell redirecting therapies	Paola Neri
09:10 - 09:20	Role of immune system as mechanism of resistance to T-cell engagers	Samir Parekh
09:20 - 09:30	Optimal dose, schedule, and timing	Surbhi Sidana
09:30 - 09:40	Toxicity management, infection management, secondary cancers and delayed neurotoxicity	Benjamin Puliafito
09:40 - 09:55	Future Directions and Challenges	Niels van de Donk
09:55 - 10:20	Round Table discussion	Adam Cohen, Hermann Einsele, Rakesh Popat

10:00 - 16:00	EXHIBITION OPEN	Hall E
10:20 - 10:30	NETWORKING BREAK	Hall E
10:30 - 12:00	INDUSTRY SYMPOSIUM SUPPORTED BY JOHNSON & JOHNSON P D V	Hall FG
	<i>Chair: Jean-Sebastien Claveau</i>	
10:30 - 10:35	Welcome and introduction of symposium theme	Jean-Sebastien Claveau
10:35 - 11:00	Tailoring Treatment Across the Spectrum in NDMM Panel Discussion and Audience Q&A	Alissa Visram
11:00 - 11:25	Optimizing Patient Selection and the CAR-T Patient Journey for RRMM Panel Discussion and Audience Q&A	Binod Dhakal
11:25 - 11:50	Enabling the Optimal Point of Care for Bispecific Antibodies in RRMM Panel Discussion and Audience Q&A	Roberto Mina
11:50 - 12:00	Final thoughts and Symposium Close	Jean-Sebastien Claveau
12:00 - 13:00	LUNCH AND POSTER SESSIONS P	Hall E
12:00 - 12:50	POSTER DISCUSSION P L	714A
	<i>Co-chairs: Craig Cole and Andrew Spencer</i>	
12:00 - 12:02	Introduction	
12:02 - 12:08	PA-084: Drivers of primary resistance to BCMA-targeted T cell redirected therapies in high tumor burden	Kirsten Pfeffer
12:08 - 12:14	PA-488: Efficacy and Safety of a China-developed BCMA-targeted CAR-T Therapy (Eque-cel) in Plasma Cell Leukemia: Real-world Multicenter Experience	Dou Xuelin
12:14 - 12:20	PA-520: Efficacy and safety of low-frequency daratumumab in systemic light-chain amyloidosis	Zhen Cai
12:20 - 12:26	PA-379: Health-related quality of life (HRQoL) in frail patients with newly diagnosed multiple myeloma (NDMM) treated with isatuximab (Isa), bortezomib, lenalidomide, and dexamethasone (Isa-VRd) vs VRd alone	Robert Orlowski
12:26 - 12:32	PA-064: Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial	Salomon Manier
12:32 - 12:38	PA-355: Real-world Impact of Anti-CD38 Monoclonal Antibodies and Hematopoietic Stem Cell Transplant in Primary Plasma Cell Leukemia (2021 IMWG Criteria): A Single-center Analysis	Vincent Luong
12:38 - 12:44	PA-145: Treatment-Free Hospitalization-Free Time With CAR T-Cell Therapy Versus Standard Regimens and Quality of Life Implications in Patients With Relapsed/Refractory MM: Findings From the KarMMa-3 Trial	Krina Patel
12:44 - 12:50	PA-295: Tumor-reactive $\gamma\delta$ T cells mediate responses to the antibody drug conjugate belantamab mafodotin in multiple myeloma	Liam Hendrikse

12:00 - 12:50	MEET THE EXPERTS P L	
Room 714B	Establishing outpatient administration of Bispecifics and immunotherapy	Yi Lin and Ajay Nooka
Room 716A	Waldenström's	Steven Treon
Room 716B	Extramedullary disease/PCI	Yael Cohen and Wilson Gonsalves
13:00 - 13:50	SPECIAL SESSION: JOINT IMS/EHA SYMPOSIUM P D V	Hall FG
	<i>Co-chairs: Philippe Moreau and Pieter Sonneveld</i>	
	Precursor States of Follicular Lymphoma	Sandrine Roulland
	CHiP	Niccolo Bolli
14:00 - 14:50	IMS AWARD CEREMONY P D V	Hall FG
14:00 - 14:10	Bart Barlogie Award	Elena Zamagni
14:10 - 14:18	Ken Anderson Award	Leif Bergsagel
14:18 - 14:50	Waldenström Award	Maria-Victoria Mateos
14:50 - 15:40	LATE BREAKING ABSTRACT SESSION P D V	Hall FG
	<i>Chairs: Kenneth Anderson and Keith Stewart</i>	
14:50 - 15:00	OA-67: Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety and Efficacy Data from the "STEM" (Sequential T Cell-Engagement for Myeloma) Trial	Adam Cohen
15:00 - 15:10	OA-65: Favorable outcome of Relapsed/Refractory Multiple Myeloma treated with Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy; IFM experience from the Descar-T Registry	Bertrand Arnulf
15:10 - 15:20	OA-66: Maintenance therapy with belantamab, pomalidomide and dexamethasone in high-risk myeloma patients: A phase 2 study with a safety run-in - interim analysis	Ajay Nooka
15:20 - 15:30	OA-63: Efficacy and Safety of Iberdomide, Daratumumab, and Dexamethasone, in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients: Initial Analysis of the GEM-IBERDARAX trial	Verónica González-Calle
15:30 - 15:40	OA-70: Patient-Reported Outcomes (PROs) and Safety in Patients (Pts) With NDMM Achieving MRD Negativity and ≥CR (MRDneg) in the Phase 3 PERSEUS and CEPHEUS Trials	Jesus San Miguel
15:40 - 16:00	NETWORKING BREAK	Hall E

16:00 - 16:50	ABSTRACT SESSION 5 P D	Room 701
	<i>Co-chairs: Nisha Joseph and Douglas Joshua</i>	
16:00 - 16:10	OA-08: Three-Year Follow-Up of FUMANBA-1: a Phase 1b/2 Study of Fully Human Anti-BCMA CAR-T Equecabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma	Lugui Qiu
16:10 - 16:20	OA-03: Development and Validation of the SCOPE-MM Score: A Pre-Apheresis Risk Model Predicting Response and Toxicity in RRMM Patients Receiving BCMA-Directed CAR-T Therapy	David Cordas dos Santos
16:20 - 16:30	OA-12: First-in-Human Phase 1 Trial of Trimeric APRIL (TriPRIL) CAR-T Cells in Relapsed or Refractory Multiple Myeloma	Benjamin Puliafito
16:30 - 16:40	OA-05: Rapid Peak CAR-T Expansion is Associated with Delayed Neurotoxicity following Ciltacabtagene Autoleucel in Multiple Myeloma	Hitomi Hosoya
16:40 - 16:50	OA-71: Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells for the treatment of relapsed or refractory multiple myeloma: Results from the phase I TANDEMM clinical trial	Saad Usmani
16:00 - 16:50	ABSTRACT SESSION 6 P D	Room 718
	<i>Co-chairs: Gareth Morgan and Lugui Qui</i>	
16:00 - 16:10	OA-01: TET2 and EZH2 genetic alterations promote malignant CAR-T transformation in anti-BCMA CAR-T therapy.	Adolfo Aleman
16:10 - 16:20	OA-09: A syngeneic mouse model of CAR-T cell therapy containing a translatable dual human/mouse reactive sdAb binder in Vk*MYC mice reveals clinically-relevant microenvironment changes	Lorenzo Lindo
16:20 - 16:30	OA-06: Inactivation of TRAF3 and CYLD Drive Resistance to T-Cell Based Therapies in Multiple Myeloma by Promoting Inflammation and an Immunosuppressive Microenvironment that Impair T Cell Function	David Jung
16:30 - 16:40	OA-04: CD4+ T-Cells Mediate Immune-Related Adverse Events (CirAE) Following BCMA CAR-T Therapy	Matthew Ho
16:40 - 16:50	OA-32: Idecabtagene vicleucel (ide-cel) and endogenous immune profiles linked to progression-free survival in relapsed/refractory multiple myeloma (RRMM) patients	Bruno Paiva
17:00 - 18:00	INDUSTRY SYMPOSIUM SUPPORTED BY ABBVIE P D V	Hall FG
	<i>Infection Risk with T-Cell Engagers in Multiple Myeloma</i>	
	<i>Chair: Ajai Chari</i>	
17:00 - 17:03	Welcome and Introductions	Ajai Chari
17:03 - 17:18	Factors Influencing Infection Risk in MM	Guido Lancman
17:18 - 17:28	Infection Risks with T-Cell Engaging Therapies	Paula Rodriguez-Otero
17:28 - 17:33	Panel discussion	
17:33 - 17:45	Strategies for Mitigating Infection Risk	Ajai Chari
17:45 - 18:00	Panel discussion	

Friday, September 19, 2025

06:30 - 18:30 **REGISTRATION OPEN** Level 600 Prefunction

08:00 - 09:00 **INDUSTRY SYMPOSIUM SUPPORTED BY PFIZER** **P D V** Hall FG

A road map for integration of treatment of Relapsed and Refractory Multiple Myeloma in the community: harnessing the power of BCMA Bispecific Antibodies – A Blueprint for Academic and Community Collaboration

Chair: Andrew Yee

08:00 - 08:05	Welcome and Introductions	Andrew Yee
08:05 - 08:20	Bringing Innovative Therapies to the Point of Care: BCMA BsAbs in Relapsed and Refractory Multiple Myeloma	Andrew Yee
08:20 - 08:30	Clinical Considerations on Safety When Using BCMA BsAbs	Albert Oriol
08:30 - 08:40	Perspectives on Community Use of BCMA BsAbs: Expanding Access to Novel Therapies	Janet MacEachern and Arlene Gayle
08:40 - 08:50	Panel Discussion: Community Use of BCMA BsAbs	
08:50 - 09:00	Conclusion and Q&A	

09:00 - 10:20 **CORE SESSION 4: RELAPSE WITHIN 1-3 LINES OF THERAPY** **P D V** Hall FG

Chair: Philippe Moreau, Co-chair: Charlotte Pawlyn

09:00 - 09:10	When to treat relapse: MRD positivity or symptomatic relapse?	Fredrik Schjesvold
09:10 - 09:20	Immunotherapy vs conventional treatment at the time of the first relapse	Amrita Krishnan
09:20 - 09:30	Functional high risk patients at relapse	Katja Weisel
09:30 - 09:40	Should lines of therapy define treatment?	Cyrille Touzeau
09:40 - 09:55	Future Directions and Challenges	Saad Usmani
09:55 - 10:20	Round Table discussion	Meletios Dimopoulos, Hang Quach, Pieter Sonneveld, Keith Stewart

10:30 - 16:30 **EXHIBITION OPEN** Hall E

10:30 - 10:45 **NETWORKING BREAK** Hall E

10:45 - 12:15 **INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI** **P D V** Hall FG

NDMM case files: Practical considerations for a patient-centric approach to anti-CD38 quadruplets

Chair: Xavier Leleu

10:45 - 11:00	Setting the scene: Exploring key considerations for assessing frontline treatment	Xavier Leleu
11:00 - 11:30	Piecing together the evidence: Individualizing anti-CD38 quads in non-transplant patients	Claudio Cerchione
11:30 - 12:00	Piecing together the evidence: Optimizing anti-CD38 quads in transplant-eligible NDMM	Elizabeth O'Donnell
12:00 - 12:15	Cracking the code: A shifting treatment paradigm to address unique patient needs	Xavier Leleu

12:15 - 13:15	LUNCH AND POSTER SESSION P	Hall E
12:15 - 13:05	POSTER DISCUSSION P L <i>Co-chairs: P.Joy Ho and Adam Sperling</i>	714A
12:15 - 12:17	Introduction	
12:17 - 12:23	PA-080: Arlocabtagene autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens	Omar Nadeem
12:23 - 12:29	PA-517: BCMA CAR-T Therapy with Radiotherapy Bridging and Maintenance Achieves Unprecedented Complete Response in Extramedullary Myeloma	Lily Zhou
12:29 - 12:35	PA-321: Belantamab Mafodotin plus Lenalidomide/ Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma: Long-Term Efficacy and Safety Results from the Phase 1/2 BelaRd Study	Evangelos Terpos
12:35 - 12:41	PA-199: Elevated Non-Clonal Bone Marrow Plasma Cell Fraction at Diagnosis Is Associated with Improved Outcomes in Multiple Myeloma	Saurabh Zanwar
12:41 - 12:47	PA-034: One-time ex-vivo conditioning of CAR-T cells with a novel metabolic modulator	Taro Hitosugi
12:47 - 12:53	PA-416: Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 study	Karthik Ramasamy
12:53 - 12:59	PA-494: Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM	Vania Hungria
12:59 - 13:05	PA-144: Whole Body Magnetic Resonance Imaging (WBMRI) for Response Evaluation in Patients with Multiple Myeloma	Ioannis Ntanasis-Stathopoulos
12:15 - 13:05	MEET THE EXPERTS P L	
Room 714B	Bone directed imaging/treatment	Suzanne Lentzsch and Elena Zamagni
Room 716A	Experimental models	Marta Chesi and Jose Martinez Climent
Room 716B	Optimizing Outcomes with limited resources	Dorotea Fantl and Pankaj Malhotra

13:15 - 15:05	PLENARY SESSION P D V	Hall FG
	<i>Co-chairs: Evangelos Terpos and Sundar Jagannath</i>	
13:15 - 13:19	Abstract Introduction	Adam Cohen
13:19 - 13:37	OA-16: BCMA CAR T-Cell Therapy in Newly Diagnosed Primary Plasma Cell Leukemia Ineligible for Transplantation: An Open Label, Single-arm, Phase 2 Study (CAREMM-002)	Chenxing Du
13:37 - 13:41	Abstract Introduction	Bruno Paiva
13:41 - 13:59	OA-30: Single-cell immune landscape associated with Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone induction efficacy in Newly Diagnosed Myeloma	Ludovic Martinet
13:59 - 14:03	Abstract Introduction	Jill Corre
14:03 - 14:21	OA-33: High-Risk Genomic Consensus Model Validation in a Large Cohort of Newly Diagnosed Multiple Myeloma Patients Using Next Generation Sequencing	Anais Schavgoulidze
14:21 - 14:25	Abstract Introduction	Richard LeBlanc
14:25 - 14:43	OA-68: Safety and efficacy of linvoseltamab (LINVO) in patients (Pts) with high-risk smoldering multiple myeloma (HR-SMM): first results from the Phase 2 LINKER-SMM1 trial	Paula Rodriguez-Otero
14:43 - 14:47	Abstract Introduction	Hira Mian
14:47 - 15:05	OA-61: A Randomized Phase 2 Study of Daratumumab, Lenalidomide, Ixazomib, and Dexamethasone in Transplant-Ineligible/Deferred Patients with Newly Diagnosed Multiple Myeloma: Alliance Foundation Trial 41	Andrew Yee
15:15 - 16:05	RINEY SESSION P D V	Hall FG
	<i>Co-chairs: Nikhil Munshi and Kenneth Anderson</i>	
15:15 - 15:17	Introduction	
15:17 - 15:29	The Role of Philanthropy in Accelerating the Understanding and Treatment of Multiple Myeloma	Bobby Sandage
15:29 - 15:41	Improving BCMA CAR T Cell Long-Term Efficacy for Reduced Relapse in Multiple Myeloma Patients	Mohammad Rashidian
15:41 - 15:53	Investigating heme-induced effector CAR T cells in multiple myeloma therapy	Mala Shanmugam
15:53 - 16:05	GCK inhibition as a new therapeutical approach in RASMut myeloma and possible strategy to overcome therapy resistance	Josefine Krüger
16:15 - 16:30	NETWORKING BREAK	Hall E
16:30 - 17:20	REGULATORY SESSION P D V	Hall FG
	<i>Co-chairs: Nikhil Munshi and Philippe Moreau</i>	
16:30 - 16:40	OA-62: Dynamic prediction of Progression based on Minimal Residual Disease (MRD) in Patients with Newly Diagnosed Transplant Eligible Multiple Myeloma	Anna Smit
16:40 - 17:20	Panel Discussion	Jenny Ahlstrom, Kenneth Anderson, Edward Laane, Vincent Rajkumar, Anna Smit

17:30 - 18:30	INDUSTRY SYMPOSIUM SUPPORTED BY GILEAD & KITE AND ARCELLX P D V	Hall FG
	<i>Chair: Sham Mailankody</i>	
17:30 - 17:35	Welcome and Introductions	Sham Mailankody
17:35 - 17:50	The Unmet Needs in Multiple Myeloma	Michael Sebag
17:50 - 18:05	The Role of CAR T-Cell Therapy in Multiple Myeloma	Judith Hecker
18:05 - 18:25	Novel Targets and the Evolving Role of CAR T	Ciara Freeman
18:25 - 18:30	Summary and Close	Sham Mailankody

Saturday, September 20, 2025

07:00 - 14:00	REGISTRATION OPEN	Level 600 Prefunction
---------------	--------------------------	-----------------------

08:00 - 08:50	ABSTRACT SESSION 7 P D	Room 701
	<i>Co-chairs: Melissa Alsina and Damian Green</i>	
08:00 - 08:10	OA-50: Iberdomide, daratumumab, and dexamethasone (IberDd) in transplant-ineligible/deferred (TNE) newly diagnosed multiple myeloma (NDMM): updated results from the CC-220-MM-001 trial	Sagar Lonial
08:10 - 08:20	OA-46: Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022-05)	Arthur Bobin
08:20 - 08:30	OA-48: Final Analysis of the GEM-BELA-VRd Phase II Trial: Belantamab Mafodotin Plus VRd in Newly Diagnosed Transplant-Eligible Myeloma After 2 Years of Maintenance with Belantamab and Lenalidomide	Verónica González-Calle
08:30 - 08:40	OA-47: Updated Efficacy and Safety Results of Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: AURIGA Study	Larry Anderson
08:40 - 08:50	OA-51: Carfilzomib, lenalidomide, and dexamethasone (KRd) after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: analysis of high-risk subset in phase 3 ATLAS trial	Andrzej Jakubowiak

08:00 - 08:50	ABSTRACT SESSION 8 P D	Room 718
	<i>Co-chairs: Wee Joo Chng and Bruno Paiva</i>	
08:00 - 08:10	OA-26: Comparative analysis of clonoSEQ MRD testing from bone marrow and circulating tumor DNA assessment in multiple myeloma	Julia Wiedmeier-Nutor
08:10 - 08:20	OA-23: Circulating tumor cells for the staging of multiple myeloma: first results of a European pooled analysis of 2432 patients with newly diagnosed multiple myeloma and plasma cell leukemia	Luca Bertamini

08:20 - 08:30	OA-25: High Accuracy of Next-Generation Flow (NGF) in Predicting Measurable Residual Disease by Next-Generation Sequencing (NGS) in the 10 ⁻⁶ Range: A Prospective Comparison Within the Phase III IsKia Trial	Mattia D'Agostino
08:30 - 08:40	OA-22: Comparative Analysis of Four NGS Protocols for Measurable Residual Disease Assessment Testing ctDNA and Bone Marrow Samples in Multiple Myeloma.	Silvia Armuzzi
08:40 - 08:50	OA-24: Assessment For Circulating Plasma Cell Enhances R2-ISS In Newly Diagnosed Multiple Myeloma	Arwa Bohra
09:00 - 09:50	ABSTRACT SESSION 9 P D <i>Co-chairs: Vania Hungria and Raphael Szalat</i>	Room 701
09:00 - 09:10	OA-58: Isatuximab subcutaneous via an on-body delivery system versus isatuximab intravenous, plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma: the randomized Phase 3 IRAKLIA study	Xavier Leleu
09:10 - 09:20	OA-54: Efficacy of Mezigdomide plus Dexamethasone and Bortezomib or Carfilzomib in patients with relapsed/refractory multiple myeloma by line of therapy: results from the phase 1/2 CC-92480-MM-002 trial	Albert Oriol
09:20 - 09:30	OA-57: IVIG and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab	Febe Smits
09:30 - 09:40	OA-59: The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Data in Relapsed/Refractory Multiple Myeloma in a Phase 1/2a clinical trial as it advances into Cohort 7	Jonathan Kaufman
09:40 - 09:50	OA-53: Functional High-Risk (FHR) Phenotype Predicts Poor Survival in Multiple Myeloma (MM) Independent of Frontline Treatment: A Secondary CIBMTR Analysis	Rahul Banerjee
09:00 - 09:50	ABSTRACT SESSION 10 P D <i>Co-chairs: Enrique Ocio and Mala Shanmugam</i>	Room 718
09:00 - 09:10	OA-42: Clonotypic B cells are passengers during malignant transformation and not drivers of disease progression in plasma cell (PC) neoplasms	Bruno Paiva
09:10 - 09:20	OA-41: Clinical Validation of Revised Diagnostic Criteria for Light Chain MGUS and Risk of Progression to Malignancy	Laerke Andersen
09:20 - 09:30	OA-44: Genomics define neoplastic transformation in multiple myeloma precursor conditions	Francesco Maura
09:30 - 09:40	OA-45: Cell-free BCL2 exRNA, but not MYC or MIZ1, identifies smouldering myeloma with a high risk of progression among patients in the Myeloma Related Disease Registry (MRDR)	Daniel Wong
09:40 - 09:50	OA-43: Monoclonal gammopathy of indeterminate potential (MGIP) as an early and premalignant stage in the evolution toward hematological malignancies	Sungjae Kim

10:00 - 10:50	FUTURE TARGETS AND NEW MODALITIES OF THERAPY P D V	Hall FG
	<i>Co-chairs: Christine Chen and Joaquin Martínez-López</i>	
10:00 - 10:01	Welcome	Christine Chen and Joaquin Martínez-López
10:01 - 10:09	AbbVie's etentamig and research pipeline demonstrate a commitment to innovation and functional cure for patients with multiple myeloma	Chetasi Talati
10:09 - 10:17	CELMoD™ Agents for the Treatment of Multiple Myeloma	Michael Amatangelo
10:17 - 10:25	New Modalities to Improve Multiple Myeloma Patient Experience and Outcomes	Jordan Schecter
10:25 - 10:33	Anitocabtagene Autoleucel: Innovation in BCMA-Targeting Therapeutics	Ana Kostic
10:33 - 10:41	Future Targets and New Modalities of Therapy: ADCs and Epigenetic Regulators in Multiple Myeloma	Arun Balakumaran
10:41 - 10:49	Next-Generation Immunotherapies for Relapsed/Refractory Multiple Myeloma (RRMM): Integrating Costimulatory Bispecific Antibody (bsAb) Signaling	Glenn Kroog
10:49 - 10:50	Close	
11:00 - 11:50	ABSTRACT SESSION 11 P D	Room 701
	<i>Co-chairs: Laura Rosinol and Jesus Berdeja</i>	
11:00 - 11:10	OA-60: Updated Interim Results of Sonrotoclast + Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM): An All-Oral Treatment	Binod Dhakal
11:10 - 11:20	OA-52: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degradable, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)	Binod Dhakal
11:20 - 11:30	OA-38: A phase I/II single arm study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in patients with relapsed multiple myeloma (MM): primary analysis. AMARC 19-02 Belacard Study	Masa Lasica
11:30 - 11:40	OA-56: Belantamab for the treatment of multiple myeloma: results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial	Hang Quach
11:40 - 11:50	OA-55: Treatment Patterns and Outcomes in Quad-Class Exposed (QCE) Relapsed Refractory Multiple Myeloma (RRMM): Investigating Critical Unmet Needs	Doris Hansen
11:00 - 11:50	ABSTRACT SESSION 12 P D	Room 718
	<i>Co-chairs: Mariateresa Fulciniti and Jill Corre</i>	
11:00 - 11:10	OA-37: Novel NKp30-directed Bispecific Natural Killer Cell Engagers Targeting GPRC5D or CD38 for the Treatment of Multiple Myeloma	Dorothee Winterberg
11:10 - 11:20	OA-40: A Novel Dual Proteasome and HDAC6 Inhibitor I3MV-8b Potentiates Anti-CD38 Monoclonal Antibody Efficacy in Multiple Myeloma	Lanting Liu

11:20 - 11:30	OA-39: Targeting PHF19 Inhibits Myeloma progression and Increases IMiDs Sensitivity by Epigenetically Regulating MYC and IRF4 Pathway	Xiyue Sun
11:30 - 11:40	OA-34: Exploring molecular glues to activate proteasomes and develop shared and personalized neoantigen-based therapeutics in multiple myeloma	James Driscoll
11:40 - 11:50	OA-64: Evidence for Pre-Existing Myeloma Cells with a Gene Expression Pattern Associated with Resistance to BCMA CAR T Cells.	Lawrence Boise
12:00 - 12:50	HIGHLIGHTS OF THE 2025 ANNUAL MEETING P D V <i>Co-chairs: Donna Reece and Rafael Fonseca</i>	Hall FG
12:00 - 12:15	Translational Research	Nizar Bahlis
12:15 - 12:30	Basic Research	Lawrence Boise
12:30 - 12:45	Clinical Research	Marc Raab
12:45 - 12:50	Q&A	
13:00 - 14:00	DEBATE ON ADCs, BISPECIFICS OR CART P D V <i>Co-chairs: Masahiro Abe and Jonathan Kaufman</i>	Hall FG
13:00 - 13:10	ADCs	Suzanne Trudel
13:10 - 13:20	Bispecifics	Noopur Raje
13:20 - 13:30	CART	Thomas Martin
13:30 - 14:00	Discussion	
14:00 - 14:30	CLOSING CEREMONY P D V	Hall FG

The IMS gratefully acknowledges the following
organizations for their sponsorship of the
22nd IMS Annual Meeting:

TITANIUM LEVEL



Johnson & Johnson

sanofi

PLATINUM LEVEL

abbvie



GSK



SILVER LEVEL

REGENERON
SCIENCE TO MEDICINE®

BRONZE LEVEL

AstraZeneca